Genomictree Inc.
228760
Rang in aandelen
#19276
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Aandeelprijs
$6.51
Marktkapitalisatie
$159.71M
Verandering (1 dag)
-1.57%
Verandering (1 jaar)
-51.70%
Land
KR
Handel Genomictree Inc. (228760)
Categorie
Healthcare
Marktkapitalisatie van Genomictree Inc.(228760)
Marktkapitalisatie: $159.71M
Vanaf October 2026 heeft Genomictree Inc. een marktkapitalisatie van $159.71M. Dit maakt Genomictree Inc. volgens onze gegevens het 19276th meest waardevolle bedrijf ter wereld op basis van marktkapitalisatie. De marktkapitalisatie is de totale marktwaarde van alle uitstaande aandelen van een beursgenoteerd bedrijf en wordt vaak gebruikt om de waarde van een bedrijf te meten.
Marktkapitalisatiegeschiedenis van Genomictree Inc. van 2017 tot 2026
228760 vergeleken met de top 5 populairste stocks
